ivii treatment Search Results


ivii treatment  (Dexcom Inc)
86
Dexcom Inc ivii treatment
CEG comparison <t>of</t> <t>CGM</t> interstital fluid glucose versus reference blood glucose in people with T1D treated with <t>IVII</t> (a: POC; b: GAS), according to insulin infusion indication (red: DKA; blue: Non‐DKA). CEG, Consensus error grid; CGM, Continuous glucose monitoring; DKA, Diabetic ketoacidosis; GAS, Blood gas; IVII, Intravenous insulin infusion; POC, Point‐of‐care; T1D, Type 1 diabetes.
Ivii Treatment, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ivii+treatment/pmc12352713-94-11-28?v=Dexcom+Inc
Average 86 stars, based on 1 article reviews
ivii treatment - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

Image Search Results


CEG comparison of CGM interstital fluid glucose versus reference blood glucose in people with T1D treated with IVII (a: POC; b: GAS), according to insulin infusion indication (red: DKA; blue: Non‐DKA). CEG, Consensus error grid; CGM, Continuous glucose monitoring; DKA, Diabetic ketoacidosis; GAS, Blood gas; IVII, Intravenous insulin infusion; POC, Point‐of‐care; T1D, Type 1 diabetes.

Journal: Diabetic Medicine

Article Title: Continuous glucose monitoring during intravenous insulin infusion treatment: Assessing accuracy to enable future clinical utility

doi: 10.1111/dme.70076

Figure Lengend Snippet: CEG comparison of CGM interstital fluid glucose versus reference blood glucose in people with T1D treated with IVII (a: POC; b: GAS), according to insulin infusion indication (red: DKA; blue: Non‐DKA). CEG, Consensus error grid; CGM, Continuous glucose monitoring; DKA, Diabetic ketoacidosis; GAS, Blood gas; IVII, Intravenous insulin infusion; POC, Point‐of‐care; T1D, Type 1 diabetes.

Article Snippet: Participants were included in this subgroup analysis if, during periods of IVII treatment, CGM ISFG measures were available from hospital‐linked web‐based CGM software accounts (LibreView, Medtronic Carelink, or Dexcom Clarity), and REF BG (POC, GAS) measures were available from hospital electronic medical records.

Techniques: Comparison

Bland–Altman plot of difference between CGM interstital fluid glucose and reference blood glucose measures during IVII (a: POC; b: GAS). 95% limits of agreement (red dotted lines) calculated as mean ± 1.96 SD. CGM, Continuous glucose monitoring; GAS, Blood gas; IVII, Intravenous insulin infusion; POC, Point‐of‐care; SD, Standard deviation.

Journal: Diabetic Medicine

Article Title: Continuous glucose monitoring during intravenous insulin infusion treatment: Assessing accuracy to enable future clinical utility

doi: 10.1111/dme.70076

Figure Lengend Snippet: Bland–Altman plot of difference between CGM interstital fluid glucose and reference blood glucose measures during IVII (a: POC; b: GAS). 95% limits of agreement (red dotted lines) calculated as mean ± 1.96 SD. CGM, Continuous glucose monitoring; GAS, Blood gas; IVII, Intravenous insulin infusion; POC, Point‐of‐care; SD, Standard deviation.

Article Snippet: Participants were included in this subgroup analysis if, during periods of IVII treatment, CGM ISFG measures were available from hospital‐linked web‐based CGM software accounts (LibreView, Medtronic Carelink, or Dexcom Clarity), and REF BG (POC, GAS) measures were available from hospital electronic medical records.

Techniques: Standard Deviation